Welcome to our dedicated page for Vicarious Surgical news (Ticker: RBOT), a resource for investors and traders seeking the latest updates and insights on Vicarious Surgical stock.
Vicarious Surgical Inc (RBOT) combines advanced robotics with virtual reality to transform minimally invasive surgery. This news hub provides investors and healthcare professionals with essential updates about the company's technological advancements and market position.
Access real-time information about surgical robotics innovations, regulatory milestones, and strategic partnerships. Our curated collection includes earnings reports, product development announcements, and clinical trial updates directly impacting the future of abdominal surgery techniques.
Key focus areas include 3D visualization systems, single-port surgical interfaces, and integration with existing hospital workflows. Stay informed about developments in robotic-assisted procedures that enhance surgical precision while reducing patient recovery times.
Bookmark this page for verified updates about RBOT's progress in medical robotics. Regularly updated content ensures you maintain current awareness of technological breakthroughs and industry partnerships shaping modern surgical practices.
Vicarious Surgical (NYSE: RBOT) has received a notice from the NYSE on April 10, 2025, indicating non-compliance with continued listing standards. The company failed to maintain both a 30-day average market capitalization and stockholders' equity above $50 million, with market cap averaging approximately $47.4 million.
The company has 45 days to submit a compliance plan to the NYSE, detailing actions to meet requirements within an 18-month cure period. During this time, RBOT stock will continue trading with a '.BC' (below criteria) designation. If the plan is not submitted timely or accepted, NYSE will initiate delisting proceedings.
The notice does not affect daily operations or SEC reporting obligations. The company is evaluating options to regain compliance with NYSE listing standards.
Vicarious Surgical (NYSE: RBOT) announced that Company President Randy Clark will transition to a Board Member role, effective April 25, 2025. As President, Clark led key business functions including product development, operations, clinical regulatory, quality affairs, and human resources.
During his tenure, Clark made significant contributions by:
- Developing manufacturing capabilities and strengthening supply chain
- Establishing key partnerships
- Implementing personnel realignment
- Streamlining business processes
- Formalizing workflows and standardizing procedures
CEO Adam Sachs acknowledged Clark's role in building a strong foundation for future growth. Clark will continue to provide strategic guidance as a Board member, ensuring his expertise remains available to the company while allowing for leadership evolution aligned with strategic and capital needs.
Vicarious Surgical (NYSE: RBOT) has reported its Q4 and full year 2024 financial results, marking significant progress with the completion of Version 1.0 System integration. The company expanded strategic partnerships with LSU Health New Orleans, Temple Health, and University of Illinois Health, while preparing for first clinical use in 2025.
Financial highlights for Q4 2024 include operating expenses of $15.0 million (down 3% YoY), with a GAAP net loss of $13.9 million ($2.36 per share). Full year 2024 saw operating expenses of $66.6 million (17% decrease YoY) and a GAAP net loss of $63.2 million ($10.74 per share).
The company ended 2024 with $49.1 million in cash and investments, achieving its 2024 cash burn guidance. For 2025, Vicarious Surgical has set a cash burn guidance of approximately $50 million. The company has appointed Sarah Romano as CFO, effective April 1st, 2025.
Vicarious Surgical (NYSE: RBOT) has appointed Sarah Romano as Chief Financial Officer, effective April 1, 2025. Romano brings decades of financial leadership experience in capital markets, particularly in the healthcare sector. She previously served as CFO of Entero Therapeutics, where she managed financial strategy and executed product in-licensing partnerships.
At her former position as CFO of Kiora Pharmaceuticals, Romano secured over $50 million in funding and led M&A activities. Her expertise includes financial strategy, operations, compliance, budget reviews, forecasting, internal controls oversight, and SEC reporting. Romano holds a Master of Accountancy from Boston College and a B.A. in Accounting from the College of the Holy Cross.
Vicarious Surgical (NYSE: RBOT) has scheduled its Fourth Quarter and Fiscal Year 2024 financial results announcement for March 17, 2025, after market close. The robotics technology company, focused on advancing robotic surgery, will host a conference call at 4:30 p.m. Eastern Time to discuss the results.
Investors can participate in the conference call by dialing +1 833-470-1428 (domestic) or +1 404-975-4839 (international) with access code 373279. A webcast will be available live and archived at the company's investor relations website.
Vicarious Surgical (NYSE: RBOT) announced that Chief Operating Officer John Mazzola will retire effective April 1, 2025, after nearly 40 years in healthcare manufacturing, supply chain, and quality control. Mazzola's responsibilities will transition to Company President Randy Clark.
According to CEO Adam Sachs, Mazzola has been key in developing manufacturing processes, enhancing product quality control, and strengthening supply chain resilience. The company states it is well-positioned for its next phase, including upcoming first clinical use cases and pivotal trial.
Vicarious Surgical (NYSE: RBOT) announced that Chief Financial Officer William Kelly will be departing the company on January 2, 2025. Kelly, who has served as CFO since January 2021, is leaving to pursue other career opportunities after nearly four years with the company.
Kelly will assist in ensuring a smooth transition of responsibilities before his departure. The company has initiated a CFO succession process and will provide updates accordingly. CEO Adam Sachs expressed gratitude for Kelly's significant contributions during his tenure.
Vicarious Surgical announced its Q3 2024 financial results. Operating expenses decreased by 17% to $17.8M from $21.4M in Q3 2023. R&D expenses dropped to $10.8M from $13.0M, general and administrative expenses fell to $5.7M from $6.9M, and sales and marketing expenses decreased to $1.2M from $1.4M. The adjusted net loss was $17.0M, or $2.87 per share, compared to $20.4M, or $3.95 per share, in the same period last year. GAAP net loss was $17.1M, or $2.90 per share, versus $15.7M, or $3.04 per share, last year. The company had $60.9M in cash and investments as of September 30, 2024, with a Q3 cash burn rate of $12.4M. Full-year 2024 cash burn is expected to be approximately $50M. CEO Adam Sachs highlighted the upcoming milestone for the Version 1.0 System integration and the goal to complete the first clinical patient within a year.
Vicarious Surgical (NYSE: RBOT) has announced it will release its third quarter 2024 financial results on November 12, 2024, after market close. The company will host a conference call at 4:30 p.m. Eastern Time to discuss the results. Investors can join via phone by dialing +1 833-470-1428 (domestic) or +1 404-975-4839 (international) using access code 246564. A webcast will be available on the company's investor relations website.
Vicarious Surgical Inc. (NYSE: RBOT), a pioneering robotics technology company focused on revolutionizing robotic surgery, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference in New York. The company's management team is set to engage in a fireside chat on Friday, September 6, 2024, at 11:30 a.m. ET.
This presentation at a major healthcare conference highlights Vicarious Surgical's commitment to showcasing its innovative approach to improving surgical procedures through advanced robotics. The company's participation provides an opportunity for investors and industry professionals to gain insights into Vicarious Surgical's technology and future plans in the rapidly evolving field of robotic-assisted surgery.
